US FDA Commissioner Scott Gottlieb intends to reorganize drug reviewers from multiple disciplines into teams that would handle a product's entire life-cycle, an attempt to break down the siloed nature of many areas within the agency.
In a Nov. 3 speech at the National Press Club, Gottlieb said agency experts that handle pre-market review also should...








